A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-
Expansion Study to Evaluate the Safety, Pharmacokinetics,
Pharmacodynamics, and Antitumor Activity of AO-176

Principal Investigator

Jacqueline Vuky

Study Purpose

The purpose of this study is to find out if the investigational drug called AO-176 is safe in people with a variety of different cancers and what effects it has on cancer.

Medical Condition(s)

epithelial ovarian carcinoma
squamous cell carcinoma of the head and neck
endometrial cancer
castration resistant prostate cancer
non-small cell lung adenocarcinoma
papillary thyroid cancer
gastric adenocarcinoma (and gastro-esophageal junction adenocarcinoma)

Eligibility Criteria

Male and Female participants of 18 years of age and older.
Diagnosed with cancer mentioned in the previous list.

Age Range

18 - 100

Healthy Volunteers Needed


Duration of Participation

The study is planned to last for about 2 ½ years. How long you participate in this study depends on side effects you may have to the study drug. It also depends on how your cancer might respond to the study drug.
If your cancer improves or stays the same and you do not have serious side effects from the study drug, you may remain in the study as long as your study doctor feels you may benefit from AO-176. However, you are free to stop taking part in this study at any time and for any reason.

Minors Included



Knight Clinical Trials Information Line


Arch Oncology

Recruitment End


Compensation Provided


Go Back